Subscribe
shutterstock_716579470_nespix-1
NESPIX / Shutterstock.com
14 August 2019AmericasSarah Morgan

Jazz Pharma buys clinical-stage biotech company

Ireland-based Jazz Pharma has acquired Virginia-based Cavion in a deal that values the clinical-stage biotech company at up to $312.5 million.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
4 February 2021   Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.
Generics
Jazz Pharma accused of pay-for-delay deals over Xyrem
14 October 2021   Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem and hiked the drug prices to increase profits when it was on the verge of bankruptcy.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Big Pharma
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
4 February 2021   Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.
Generics
Jazz Pharma accused of pay-for-delay deals over Xyrem
14 October 2021   Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem and hiked the drug prices to increase profits when it was on the verge of bankruptcy.

More on this story

Big Pharma
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
4 February 2021   Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.
Generics
Jazz Pharma accused of pay-for-delay deals over Xyrem
14 October 2021   Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem and hiked the drug prices to increase profits when it was on the verge of bankruptcy.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers